logo
  

Amended: France's BIOCORP, Merck Sign Partnership To Develop Specific Version Of Mallya Device

French medical devices maker BIOCORP announced Thursday an agreement with Merck (MKGAY.PK), a science and technology company for the development and supply of a specific version of Mallya device to monitor treatment adherence in the field of Human Growth Hormone or HGH.

Following the development of the device, the companies plan to market the product on a global scale.

Following the completion of different milestones, Merck will pay around 3 million euros for the development of the specific solution. After the development phase, BIOCORP will manufacture the commercial units on behalf of Merck, which will generate additional revenues.

Mallya, manufactured in Clermont-Ferrand in France, is a Bluetooth enabled clip-on device for pen injectors. It collects dose and time of each injection and transfers information in real time to a companion software.

The device will help patients, including children and teenagers, automatically keep track of their HGH daily injection and monitor adherence with their treatment plan.

The company noted that Mallya is the first in its category to receive the CE-mark (medical device). Commercial versions for insulin pen injectors are already available and distributed in Europe and other geographies.

[corrects and replaces Merck & Co Inc. (MRK) with Merck (MKGAY.PK)]

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022. Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and...
Follow RTT